Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.

Authors

Institutions

Publication Details

Journal
Blood Cancer Discovery
Published
2025-04-15
DOI
https://doi.org/10.1158/2643-3230.bcd-24-0274
Citations
1
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
1.77

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

Iria Vázquez, Sarai Sarvide, Laura Rosiñol, Felipe de Arriba et al.
1 citations
Blood Cancer Discovery
Multiple Myeloma Research and Treatments
1.77
article

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

Iria Vázquez, Sarai Sarvide, Laura Rosiñol, Felipe de Arriba, Juan José Lahuerta, Jesús F. San Miguel, Catarina Maia, María‐Victoria Mateos, Diego Alignani, Joan Bladé, Irache Erdozain, Joaquín Martínez‐López, Marta Sonia González, Cristina Pérez, María José Larráyoz, María‐Teresa Cedena, Noemí Puig, Camila Guerrero, Albert Oriol, Bruno Paiva, Valentín Cabañas, Ana Pilar González, José M. Moraleda, Luis Palomera, Marı́a José Calasanz, Oihane Churruca, Jesús Martín, Rafael Ríos, Amagoia Mañú, Natalia Gordillo
article en
1 citations

Abstract

SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.

Blood Cancer DiscoveryVol. 6(3)
Hospital General Universitario Morales Meseguer (ES), Hospital Universitario 12 De Octubre (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Central de Asturias (ES), Clinica Universidad de Navarra (ES), Hospital Clínico Universitario Lozano Blesa (ES), Centro de Investigación del Cáncer (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario Virgen de la Arrixaca (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitari Germans Trias i Pujol (ES)
International Myeloma Foundation, Cancer Research UK, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Fondazione Regionale per la Ricerca Biomedica, Instituto de Salud Carlos III, HORIZON EUROPE European Research Council
Good health and well-being
Openalex Percentile: Top 17%
Multiple Myeloma Research and Treatments
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.